Welcome to our dedicated page for Vertex Pharmaceuticals news (Ticker: $VRTX), a resource for investors and traders seeking the latest updates and insights on Vertex Pharmaceuticals stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Vertex Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Vertex Pharmaceuticals's position in the market.
Vertex Pharmaceuticals reported a 13% increase in product revenue to $2.69 billion in Q1 2024 compared to Q1 2023. They submitted filings for vanzacaftor triple in CF to FDA and EMA, initiated NDA submission for suzetrigine in acute pain, and agreed to acquire Alpine Immune Sciences. Vertex's full year 2024 guidance includes product revenue of $10.55 to $10.75 billion.
Vertex Pharmaceuticals (Nasdaq: VRTX) has received European Commission approval for the label expansion of KALYDECO® (ivacaftor) to treat infants as young as 1 month old with cystic fibrosis (CF) who possess specific mutations in the CFTR gene. This milestone approval signifies a significant advancement in early CF treatment, potentially slowing disease progression. The expanded indication will provide eligible patients in several European countries access to this groundbreaking therapy. In the U.K., infants aged 1 month and older will also benefit from this expanded indication, following MHRA approval by the end of 2023.